Free Trial
NASDAQ:PHAT

Phathom Pharmaceuticals Q2 2023 Earnings Report

Phathom Pharmaceuticals logo
$8.15 -0.39 (-4.52%)
As of 11:37 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Phathom Pharmaceuticals EPS Results

Actual EPS
-$0.84
Consensus EPS
-$0.95
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

Phathom Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Phathom Pharmaceuticals Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Phathom Pharmaceuticals' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Phathom Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Phathom Pharmaceuticals and other key companies, straight to your email.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals (NASDAQ:PHAT), biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

View Phathom Pharmaceuticals Profile

More Earnings Resources from MarketBeat